CardieX (ASX:CDX) formally lodged its application with the Therapeutic Goods Administration for the inclusion of the CONNEQT Pulse device in the government authority's register, according to a Tuesday filing with the Australian bourse.
The US Food and Drug Administration-approved device provides arterial health insights that are useful in managing cardiovascular disease, the filing said.
The registration process is expected to take three to six months, per the filing.
CardieX's shares rose 8% in recent trade.
Price (AUD): $0.06, Change: $+0.0040, Percent Change: +7.69%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.